retatrutide triple agonist obesity phase 2 trial produces up to 30.3% weight loss in 3 Phase 2 Trial of Retatrutide

As use expanded, reports of serious adverse effects followed

The frequency may remain daily, but the dose titration often proceeds much more slowly, with longer intervals between increases

Pipeline and Technology Innovation Analysis GLP-1 Weight Loss Drug Market Pipeline: Triple Agonists, Oral Formulations, and Amylin Combinations Define the 20262035 Innovation Frontier Key GLP-1 Pipeline Molecules, Mechanisms, Development Stage, and Peak Sales Projections Triple agonist therapies targeting GLP-1, GIP, and glucagon receptors simultaneously represent the most significant efficacy advance in obesity pharmacotherapy since semaglutide

In their subsequent 4-year follow-up with 19 patients of the cohort, 45 the Lysholm score, IKDC score, and KOOS were further improved